100% Original Liraglutide - Desmopressin acetate for injection – JYMed

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We can easily normally satisfy our respected buyers with our excellent high-quality, excellent selling price and good service due to we've been far more expert and more hard-working and do it in cost-effective way for Enfuvirtide Acetate Exporter, 17-Pentaoxo-1-Thia-4, Fertirelin Acetate Exporter, With us your money in safe your business in safe . Hope we can be your trustworthy supplier in China . Looking forward for your cooperation .
100% Original Liraglutide - Desmopressin acetate for injection – JYMed Detail:

1ml:4μg / 1ml:15μg   Strength

Indication:

INDICATIONS AND USAGE

Hemophilia A: Desmopress in Acetate Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%.

Desmopress in acetate injection will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure.

Desmopress in acetate injection will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding.

Desmopress in acetate injection is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies.

In certain clinical situations, it may be justified to try desmopress in acetate injection in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored. von Willebrand’s Disease (Type I): Desmopres s in acetate injection 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrand’s disease (Type I) with factor VIII levels greater than 5%. Desmopress in acetate injection will often maintain hemostasis in patients with mild to moderate von Willebrand’s disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure.

Desmopress in acetate injection will usually stop bleeding in mild to moderate von Willebrand’s patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding.

Those von Willebrand’s disease patients who are least likely to respond are those with severe homozygous von Willebrand’s disease with factor VIII coagulant activity and factor VIII von

Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of desmopress in acetate injection to ensure that adequate levels are being achieved.

Desmopress in acetate injection is not indicated for the treatment of severe classic von Willebrand’s disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen.

Diabetes Insipidus: Desmopress in acetate injection 4 mcg/mL is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region.

Desmopress in acetate injection is ineffective for the treatment of nephrogenic diabetes insipidus.

Desmopress in acetate is also available as an intranasal preparation. However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate.

These include poor intranasal absorption, nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery.

CONTRAINDICATIONS

Desmopress in acetate injection 4 mcg/mL is contraindicated in individuals with known hypersensitivity to desmopress in acetate or to any of the components of desmopress in acetate injection 4 mcg/mL.

Desmopress in acetate injection is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50ml/min).

Desmopress in acetate injection is contraindicated in patients with hyponatremia or a history of hyponatremia.


Product detail pictures:

100% Original Liraglutide - Desmopressin acetate for injection – JYMed detail pictures


Related Product Guide:
Form 20-F Galmed Pharmaceuticals For: Dec 31 | Synthetic Angiotensin Ii Gmp Provider From China
Debiopharm Group Regains the Commercial Rights to Trelstar® (Triptorelin pamoate) and Looks for New Partners in North America | Lanreotide

Our primary objective is always to offer our clients a serious and responsible small business relationship, offering personalized attention to all of them for 100% Original Liraglutide - Desmopressin acetate for injection – JYMed , The product will supply to all over the world, such as: Eindhoven, Norwegian, Austria, For many years, we now have adhered to the principle of customer oriented, quality based, excellence pursuing, mutual benefit sharing. We hope, with great sincerity and good will, to have the honor to help with your further market.
  • The company can keep up with the changes in this industry market, product updates fast and the price is cheap, this is our second cooperation, it's good.
    5 Stars By Sara from Cairo - 2015.02.21 12:14
    High Quality, High Efficiency, Creative and Integrity, worth having long-term cooperation! Looking forward to the future cooperation!
    5 Stars By Zoe from Poland - 2015.06.30 17:29
    Write your message here and send it to us